Loading
NASDAQHealthcareBiotechnology
Latest quote
$30.43
−$0.575 · -1.85%
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Previous close
$30.43
−$0.575 · -1.85%
After-hours
$30.51
+$0.08 · +0.26%
Oct 7, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Day range
Current $30.43
52-week range
Current $30.43
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
10
Overpriced
Sentiment
59
Mixed
Risk
34
Moderate Risk
Momentum
70
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Day range
Current $30.43
52-week range
Current $30.43
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.5M USD | 7.02M USD | 6.88M USD | 2.36M USD | 4.65M USD |
| Cost of goods sold | — | 163.55M USD | 118.01M USD | 82.26M USD | 53.31M USD |
| Gross profit | 1.5M USD | −156.53M USD | −111.13M USD | −79.9M USD | −48.66M USD |
| Research and development | 245.1M USD | 163.55M USD | 118.01M USD | 82.26M USD | 56.81M USD |
| Selling, general, and administrative | 43.8M USD | 38.55M USD | 30.91M USD | 27.2M USD | 20.49M USD |
| Operating expenses | 288.9M USD | 38.55M USD | 43.41M USD | 35.33M USD | 22.58M USD |
| Interest income | 28.61M USD | 37.22M USD | 13.11M USD | 2.91M USD | 505K USD |
| Depreciation and amortization | 3.38M USD | 3.18M USD | 3.01M USD | 2.9M USD | 3.07M USD |
| Operating income | −287.4M USD | −195.08M USD | −154.54M USD | −115.23M USD | −71.24M USD |
| Net income | −258.8M USD | −157.86M USD | −141.43M USD | −112.33M USD | −70.51M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$66.80
119.52% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI98.96M0.00%2.3T USD0.03%$381.03-0.40%
iShares Russell 2000 ETFIWM63.18M0.08%78.56B USD0.19%$277.7-1.29%
State Street SPDR S&P Biotech ETFXBI52.07M0.50%10.08B USD0.35%$150.23-0.44%
Vanguard Extended Market ETFVXF36.21M0.04%95.4B USD0.05%$233.49-1.56%
iShares Russell 2000 Growth ETFIWO18.38M0.13%14.25B USD0.24%$355.37-1.43%
Vanguard Russell 2000 ETFVTWO17.8M0.10%18B USD0.06%$112.21-1.26%
Dimensional - US Small Cap ETFDFAS14.5M0.04%34.14B USD0.31%$77.92-1.38%
Schwab U.S. Small-Cap ETFSCHA12.64M0.06%22.01B USD0.03%$32.61-1.47%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
